In the phase III OlympiAD trial (NCT02000622), olaparib (300 mg, twice daily) monotherapy was found to be more effective than standard therapy in patients with metastatic HER2 − breast cancer and germline breast cancer gene (gBRCA) mutations in terms of prolonging progression-free survival (2.8 months) and reducing death (42%) [46]. The gene discussed is ERBB2; the disease is breast cancer.